Menu

Stevanato Group S.p.A. STVN

Full chart Compare
Set alert

Price alert · STVN

All alert types
13.57 USD +0.36 (+2.73%)

At closeNov 6, 2026, 4:09 PM EST

13.57 0.00 0.00%

After hours · Nov 6, 4:09 PM ET

12.85 Day range 13.65
13.21 52-week range 24.41
YTD
-32.55%
1 year
-44.41%
Market cap
3.71B
Revenue (ttm)
1.25B
Profit margin
11.25%
EPS (ttm)
0.59
Shares out
49.83M
P/E ratio
23.00
Forward P/E
18.63
Dividend
0.06 (0.47%)
Ex-dividend date
Jun 10, 2026
YTD return
-32.55%
1-year return
-44.41%
Volume
1.37M
Avg volume
579.58K
Open
13.23
Previous close
13.21
Day's range
12.85 – 13.65
52-week range
13.21 – 24.41
Beta
0.80
Analysts
Buy
Price target
22.04 (+62.4%)
Earnings date
Mar 3, 2027

ALL -6.10 (-31.01%)

203020212022202320242025202613.57

Key statistics

Enterprise value
3.96B
PEG ratio
0.94
Price / sales
2.95
Price / book
2.06
Dividend yield
0.47%
Payout ratio
10.59%
Revenue growth
7.60%
Free cash flow
-65.24M
Total cash
116.02M
Total debt
471.43M
Return on equity
9.26%
Short % of float
1.97%
50-day average
19.99
200-day average
18.01

Financials — quick view

All financials
STVN Revenue — quarterly 326.06M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
STVN Net income — quarterly 41.84M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
STVN EPS — quarterly 0.15
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

STVN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 3, 2027Dec 30, 20260.21———
Nov 3, 2026Sep 30, 20260.17750.180.00+1.41%
Aug 4, 2026Jun 30, 20260.14480.16+0.02+10.50%
May 7, 2026Mar 31, 20260.120.13+0.01+8.33%
Mar 4, 2026Dec 31, 20250.200.21+0.01+5.00%
Nov 6, 2025Sep 30, 20250.140.16+0.02+14.29%

Upgrades / downgrades

STVN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 4, 2026William BlairdownOutperformMarket Perform
Nov 4, 2026UBSmainNeutralNeutral
Nov 4, 2026CitigroupmainBuyBuy
Sep 9, 2026UBSmainNeutralNeutral
Jun 16, 2026TD Coweninit—Buy
Mar 6, 2026Morgan StanleymainEqual-WeightEqual-Weight

About Stevanato Group S.p.A.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
Italy

News

Your note

Sign in to keep a note on STVN — it syncs with the Stock Master app.

Insider holders

STVN insider holders
InsiderRelationLatest transactionDateShares held
BALACHANDRAN MADHAVENDirectorSaleJun 14, 202669,458
DAL LAGO MARCOChief Financial OfficerSaleAug 6, 202681,144
FEDERICI WILLIAM JDirectorSaleJun 14, 202658,580
FLYNN KAREN ADirectorSaleJun 14, 20265,757
LIN SUE-JEANDirectorStock Award(Grant)Jun 11, 20266,975
MAGISTRETTI ELISABETTADirectorSaleAug 6, 20262,930

Institution ownership

STVN institution ownership
Holder% heldSharesValueReported
Neuberger Berman Group, LLC1.86%5,622,26975.90MJun 29, 2026
Conestoga Capital Advisors, LLC1.85%5,596,51575.55MSep 29, 2026
Times Square Capital Management, LLC1.07%3,252,89943.91MSep 29, 2026
Van Berkom & Associates Inc.0.94%2,858,32338.59MSep 29, 2026
Artisan Partners Limited Partnership0.86%2,601,59835.12MJun 29, 2026
BAMCO Inc.0.82%2,494,87133.68MJun 29, 2026

Fund ownership

STVN fund ownership
Holder% heldSharesValueReported
Conestoga Funds-Conestoga Small Cap Fund1.15%3,484,75147.04MJun 29, 2026
NEUBERGER BERMAN EQUITY FUNDS-Neuberger Genesis Fund1.00%3,041,14141.06MSep 29, 2026
BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd.0.56%1,681,42922.70MJun 29, 2026
American Century Mutual Funds, Inc.-Small Cap Growth Fund0.32%977,76513.20MSep 29, 2026
Artisan Partners Funds Inc.-Artisan Small Cap Fund0.28%837,77311.31MJun 29, 2026
AMG Funds-AMG TimesSquare Mid Cap Growth Fund0.22%653,1378.82MJun 29, 2026